Sorrento Therapeutics, Inc. and Servier have entered a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento’s fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110.   Sorrento’s G-MAB library platform was used to identify and generate STI-A1110, which targets PD-1, one of the key targets in immuno-oncology therapies. Servier has an exclusive worldwide license to STI-A1110 mAb covering all indicatio...